ChemExpress Subsidiary Clears U.S. FDA Inspection to Expand American Market Access
Shanghai, Tuesday, 18 August 2026.
ChemExpress subsidiary 2Y-Biopharma achieved a flawless U.S. FDA pre-approval inspection with zero citations, paving the way to manufacture and export commercial drug products into the American market.
ChemExpress Subsidiary Clears U.S. FDA Inspection to Expand American Market Access
ChemExpress subsidiary 2Y-Biopharma achieved a flawless U.S. FDA pre-approval inspection with zero citations, paving the way to manufacture and export commercial drug products into the American market. The successful regulatory milestone clears a major hurdle for commercial drug product manufacturing and export to the United States market, strengthening ChemExpress’s position as a contract development and manufacturing organization (CDMO) capable of meeting stringent global compliance standards [1]. This development marks a significant step for the Shanghai-based company as it navigates the complex landscape of international pharmaceutical regulations [2].
Inspection Details and Regulatory Outcomes
The U.S. Food and Drug Administration (FDA) conducted the Pre-Approval Inspection (PAI) at the 2Y-Biopharma facility between June 22 and June 26, 2026 [1][2]. Following the inspection, the site received its Establishment Inspection Report (EIR) with zero Form 483 observations, indicating full compliance with current Good Manufacturing Practice (cGMP) regulations at the time of the visit [1]. The period between the conclusion of the inspection on June 26 and the public announcement on August 18, 2026, spanned 53 days, reflecting the administrative timeline for report finalization and corporate communication [1][2]. Achieving zero observations is a critical metric for CDMOs, as Form 483 citations can delay product approvals and impact client confidence in the manufacturing partner’s capabilities [1].
Strategic Implications for U.S. Market Entry
This positive inspection outcome further strengthens the regulatory compliance foundation for the drug product business as the company expands into the U.S. market [1]. 2Y-Biopharma operates as a wholly owned cGMP drug product manufacturing plant established in 2017 under the ChemExpress Group [1]. The facility supports pharmaceutical programs from formulation development and scale-up through GMP manufacturing and commercialization for markets in the United States, Europe, and China [1]. By securing this clearance, ChemExpress enhances the global competitiveness of its drug product capabilities, allowing it to service clients requiring FDA-compliant manufacturing for innovative or generic drugs [1].
Company Background and Capabilities
Shanghai Haoyuan ChemExpress Co., Ltd., traded on the Shanghai Stock Exchange under ticker SSE: 688131, was founded in 2006 and operates as a CRO/CDMO focusing on small molecules, biologics, ADCs/XDCs, peptides, and PROTACs [1]. The company employs between 1,001 and 5,000 people and maintains a platform that includes spray drying, hot-melt extrusion, lyophilization, and fluidized-bed amorphous solid dispersion (ASD) [1][2]. Over the past five years, from 2021 to 2026, ChemExpress and 2Y-Chem have supported over 14 Marketing Authorization Holder (MAH) clients in obtaining marketing approval for innovative or generic drugs [1]. Additionally, 2Y-Chem has over 20 years of experience and has serviced more than 200 New Molecular Entity (NME) projects globally, ranging from preclinical to commercial stages [1].
Upcoming Industry Engagement
Looking ahead, ChemExpress is scheduled to exhibit at CPHI Korea 2026 in Seoul, Korea, from August 25 to August 27, 2026, at Booth K29 [2]. This event will provide an opportunity to discuss project support ranging from drug discovery to commercialization, leveraging the recently validated manufacturing capabilities [2]. The company continues to emphasize its expertise in connecting scientific research with scalable pharmaceutical manufacturing to advance therapies, as reflected in its promotional activities and strategic partnerships [2]. This upcoming appearance follows closely on the announcement of the FDA inspection success, highlighting a period of active market engagement for the firm [2].